MELOXICAM (meloxicam) by Ascentage Pharma is cyclooxygenase inhibitors [moa]. First approved in 2004.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
Meloxicam is an oral NSAID suspension that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is used to treat inflammatory conditions, though specific indications are not detailed in available data. The drug works as a small-molecule COX inhibitor targeting inflammatory pathways.
As a near-LOE product, expect a smaller, defensive team focused on maintaining market share against generics rather than expansion.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Worked on MELOXICAM at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on meloxicam in its LOE-approaching stage means joining a mature, defensive team prioritizing market retention and cost optimization over growth. This is a solid foundation for commercial professionals but offers limited advancement opportunity within the product itself.